Breye Therapeutics ApS — Credit Rating and Financial Key Figures
CVR number: 40279865
Agern Alle 24, 2970 Hørsholm
Income statement (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Other operating income | 138.46 | 13.75 | |||
| External services | - 673.85 | -2 896.50 | -7 812.13 | ||
| Gross profit | 356.30 | -67.53 | - 535.39 | -2 882.75 | -7 812.13 |
| Employee benefit expenses | - 247.29 | -1 013.69 | -1 716.58 | -6 406.88 | |
| Other operating expenses | -6 640.32 | -15 236.75 | -60 742.15 | ||
| Total depreciation | - 411.17 | ||||
| EBIT | 356.30 | - 314.82 | -8 189.40 | -19 836.07 | -75 372.33 |
| Other financial income | 167.14 | 33.94 | 817.19 | ||
| Other financial expenses | -12.91 | -27.65 | -1 231.95 | - 900.03 | -1 090.61 |
| Net income from associates (fin.) | -1 540.45 | -74.77 | |||
| Pre-tax profit | 343.39 | - 342.47 | -10 794.66 | -20 776.94 | -75 645.75 |
| Income taxes | -78.96 | 52.80 | 6 202.06 | 5 495.70 | |
| Net earnings | 264.43 | - 289.67 | -10 794.66 | -14 574.88 | -70 150.06 |
Assets (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Development expenditure | 5 603.00 | ||||
| Intangible rights | 5 955.75 | 5 558.70 | |||
| Intangible assets total | 5 603.00 | 5 955.75 | 5 558.70 | ||
| Machinery and equipment | 31.77 | 17.65 | |||
| Tangible assets total | 31.77 | 17.65 | |||
| Holdings in group member companies | 26.03 | 0.01 | 0.01 | 0.01 | |
| Other receivables | 52.74 | 54.06 | |||
| Investments total | 26.03 | 0.01 | 52.75 | 54.07 | |
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 219.41 | ||||
| Current amounts owed by group member comp. | 202.80 | 251.42 | 153.68 | 472.39 | |
| Prepayments and accrued income | 240.00 | 1.25 | 155.87 | 314.33 | |
| Current other receivables | 140.81 | 361.17 | 878.18 | 2 265.24 | |
| Current deferred tax assets | 6 202.06 | 5 500.00 | |||
| Short term receivables total | 459.41 | 343.61 | 613.84 | 7 389.79 | 8 551.95 |
| Cash and bank deposits | 14.27 | 8 201.58 | 2 514.39 | 11 385.34 | 46 499.49 |
| Cash and cash equivalents | 14.27 | 8 201.58 | 2 514.39 | 11 385.34 | 46 499.49 |
| Balance sheet total (assets) | 473.68 | 14 174.23 | 3 128.24 | 24 815.40 | 60 681.86 |
Equity and liabilities (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 50.00 | 53.50 | 53.50 | 133.03 | 325.09 |
| Other reserves | 4 370.34 | ||||
| Retained earnings | -4 105.91 | -5 628.24 | 28 968.23 | 118 310.44 | |
| Profit of the financial year | 264.43 | - 289.67 | -10 794.66 | -14 574.88 | -70 150.06 |
| Shareholders equity total | 314.43 | 28.26 | -16 369.40 | 14 526.38 | 48 485.47 |
| Provisions | 52.80 | ||||
| Non-current loans from credit institutions | 13 814.34 | 18 477.98 | 7 100.90 | 3 766.81 | |
| Non-current liabilities total | 13 814.34 | 18 477.98 | 7 100.90 | 3 766.81 | |
| Current loans from credit institutions | 527.00 | 3 090.00 | |||
| Current trade creditors | 20.00 | 224.45 | 909.68 | 2 526.49 | 4 766.55 |
| Current owed to participating | 8.77 | 8.77 | 8.77 | 8.77 | |
| Short-term deferred tax liabilities | 27.39 | ||||
| Other non-interest bearing current liabilities | 50.29 | 98.41 | 101.20 | 125.87 | 573.03 |
| Current liabilities total | 106.45 | 331.63 | 1 019.65 | 3 188.12 | 8 429.58 |
| Balance sheet total (liabilities) | 473.68 | 14 174.23 | 3 128.24 | 24 815.40 | 60 681.86 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.